Beijing, China – March 22, 2022 – Ainnocence, Inc. of San Jose, California, is pleased to announce a CRO services partnership with Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services. Under the terms of this partnership, Sino…
SAN DIEGO, California., June 13, 2022 /PRNewswire/ — Ainnocence, a global biotech startup on a mission to accelerate drug discovery using a fast, self-evolving AI drug design platform, launched today at the 2022 BIO International Convention (booth 4001). Founded by a versatile team of biomedical scientists and computer scientists, Ainnocence provides small- and large-molecule design…
Artificial intelligence has the advantage of allowing for the analysis of big and ever-changing data such as the dynamic genome information of a constantly evolving virus. In this study, we have applied AI technologies in the computational design of broad neutralization antibodies against over 1300 different historical SARS-CoV-2 strains with very small computational cost. The…
Lurong Pan is the founder and Chief Executive Officer of Ainnocence, a firm seeking to accelerate drug discovery efforts through comprehensive AI models. We caught up with Lurong Pan during our Medicinal Chemistry Strategy Meeting in Boston, 2022 where we explored her motivations in the industry, and the impact of Artificial Intelligence (AI) in the…
